Please assess the completion status of the following clinical trial:

Trial Title: Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Infants aged 42 to 89 days inclusive on the day of inclusion.~* Born at full term of pregnancy (\>37 weeks).~* Informed consent form signed by the parent(s) or legally authorized representative.~* Able to attend all scheduled visits and to comply with the study procedures.~* Parent or legally authorized representative has access to a telephone.~* Parent or legally authorized representative able to read and write in English or French.~Exclusion Criteria:~* Participation in another clinical trial in the 4 weeks preceding the first trial vaccination.~* Planned participation in another clinical trial during the present trial period.~* Personal or immediate family history of congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy.~* Known or suspected systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing the same substances as the trial vaccine(s).~* Chronic illness that could interfere with trial conduct or completion.~* Received blood or blood-derived products since birth.~* Any vaccination preceding the first trial vaccination or planned in the 4 weeks after any trial vaccination (flu vaccine may be given a minimum of 4 weeks prior to the first study vaccination).~* Previous vaccination with any acellular pertussis- (DTaP) or whole cell pertussis- (DTwP) based combination vaccines, Haemophilus influenzae type b (Hib)-conjugate, poliovirus, hepatitis B, or pneumococcal conjugate vaccines.~* Coagulation disorder contraindicating IM vaccination.~* Clinically significant findings on review of systems (determined by investigator or sub-investigator to be sufficient for exclusion).~* Developmental delay or neurological disorder.~* Any condition which, in the opinion of the investigator, would interfere with the evaluation of the vaccine or pose a health risk to the subject.~* Documented Hepatitis B surface Antigen (HBsAg) seropositivity in the child or his/her mother.~* History of Hib, hepatitis B, diphtheria, tetanus, pertussis or poliovirus disease.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 89 Days
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): None
- Group B (Type: EXPERIMENTAL): None
- Group C (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).